Time filter

Source Type

Pharmacia was a pharmaceutical and biotechnological company in Sweden that merged with the American pharmaceutical company Upjohn in 1995. Wikipedia.

Pharmacia | Date: 2011-09-29

The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus.

Crystalline forms of the p38 kinase inhibitor 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide is provided. Also provided are combinations and pharmaceutical compositions comprising the crystalline forms, and methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amount of the crystalline forms.

Pharmacia | Date: 2010-06-16

Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.

Pharmacia | Date: 2011-06-16

Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.

News Article | August 29, 2016
Site: www.rdmag.com

The R&D Index: Market Watch for the week ending Aug. 26, 2016 closed at 1,540.31 for the 25 companies in the R&D Index. The Index was down -0.65 percent (or 10.2 basis points) over the week ending Aug. 19, 2016. Only seven companies gained value from 0.06 percent (Intel) to 2.72 percent (Cisco), while 18 companies lost value from -0.14 percent (Oracle) to -3.02 percent (Roche). Following a protracted bidding war with Sanofi R&D Index member Pfizer announced last week that it would purchase biotech Medivation and its prostate cancer drug Xtandi for $14 billion—more than double the $6 billion that Medivation was valued at earlier this year. Pfizer is well known for purchasing other biopharms over the past 10 years to fill its pipeline with blockbuster drugs. The other firms that Pfizer has acquired include Warner-Lambert in 2000 for $112 billion, Pharmacia in 2002 for $60 billion, Wyeth in 2009 for $68 billion and King Pharmaceuticals for $3.6 billion in 2010. Pfizer agreed to acquire Allergen in 2015 for $150 billion, which fell through after the Obama Administration targeted the deal with new M&A rules. Pfizer is considering breaking its organization into two companies—one for fast-growing brand-name drugs and another for drugs that have lost patent protection. Last week's news concerning the Fed's decision on whether or not to increase short-term interest rates turned in favor increasing rates following comments by Fed Chair Janet Yellen at a meeting on Friday. Yellen cited continued solid performance in the labor market, inflation, and economic activity over the past three months as justification for a rate increase at the Fed's next policy meeting on Sept. 20-21. Yellen clarified her recommendation would depend on the Labor Department's September 2 jobs report for August. Employers have added an average of 190,000 jobs/month in May, June and July. According to the CME Group, there is a 36 percent probability of a rate increase, which is significantly lower than it was earlier this Spring. A report by China General Administration of Customs (imports) noted last week that oil production in China may have peaked and that its imports have continued to grow and will accelerate in the years to come. China is the fourth-largest oil producer and this news implies that oil prices in the future could rise as China steps up imports to meet its domestic demands. China's current oil fields are aging and new discoveries at home have not matched its increases in demand. PetroChina, the country's largest oil producer announced last week that production fell 4 percent in the first half of 2016, double the pace of decline in 2015. China Petroleum & Chemical also noted that its crude production fell over 12 percent in the same period. China recently announced its first foreign military outpost in Djibouti, Africa, which was established in part to safeguard oil fields on which it relies. R&D Index is a weekly stock market summary of the top international companies involved in research and development. The top 25 industrial spenders of R&D in 2014 were selected based on the latest listings from Schonfeld & Associates' June 2015 R&D Ratios & Budgets. These 25 companies include pharmaceutical (11 companies), automotive (5), ICT  (7) and conglomerate (2) organizations who invested a cumulative total of more than $170 billion in R&D in 2014, or approximately 10.8% of all the R&D spent in the world by government, industries and academia combined, according to R&D Magazine's 2014 Global R&D Funding Forecast. The stock prices used in the R&D Index are tabulated from NASDAQ, NYSE, XETRA and OTC common stock prices (in U.S. dollars) for the companies selected at the close of stock trading business on the Friday preceding the publication of the R&D Index in R&D Magazine's R&D Daily eNewsletter. The companies used in the R&D Index include Microsoft, Intel, Roche Holdings, Novartis, Johnson & Johnson, Pfizer, Toyota Motor, General Motors, Merck & Co., Ford Motor, Cisco, Apple Computer, Sanofi SA, Qualcomm, IBM, Astra Zeneca plc, Honda Motor, Daimler, Oracle, GlaxoSmithKline, Siemens, Eli Lilly Co., Ericsson, Bristol-Myers Squibb and Bayer AG. Stock prices are based on those stocks traded on the U.S. exchanges. R&D Index trends (in the stock prices) are just one indicator of the amount of capital available to these high-technology companies to invest in R&D and should not be implied to indicate the absolute value of R&D investments made by these organizations. The companies chosen for the R&D Index have very large sophisticated internal and global R&D organizations with each company investing between $4.3 and $11.7 billion annually on their R&D efforts.

Discover hidden collaborations